65,437 trials
Atrial Fibrillation
Primary: Correlation Between HFS (High Frequency Stimulation) Response and CT Identified Epicardial Adipose Tissue. — 3 Number of patients with HFS response
Tympanic Membrane Perforation
Primary: Number of Serious Adverse Events — 0 Serious Adverse Event
Covid19
Primary: Change in Activated Partial Thromboplastin Time (APTT) > 1.5 Seconds — 0.95; 1.10 ratio
Herpes Zoster
Primary: Magnitude of Varicella-Zoster Virus (VZV) DNAemia — NA; NA; NA; NA DNA copies per/mL
Sudden Cardiac Arrest
Primary: Inappropriate Shock Rate — 0.333 inappropriate shocks per 100 pt-months
Anxiety · Obsessive-Compulsive Disorder
Primary: Mean Change From Baseline in Subjective Units of Distress Scale (SUDS) at End of Session 1 — -3.7; -3.6 units on a scale
Plaque, Dental · Gingivitis
Primary: Change of Navy Plaque Index (Navy Pl) After One-time Brushing — 367.5; 346.5; 355; 145.4 score on a scale
Colorectal Cancer · Polyp, Colonic
Primary: The Percent of Colonic Polyps Which Have a Visible Contrast to the Healthy Colonic Mucosa During Colon Capsule Endoscopy (CCE) — 58.3; 66.7; 0; 0 percentage of polyps…
PTSD · Physical Injury
Primary: Number of Patients With 1 or More Emergency Department Visits Per Quarter — 225; 225; 90; 79 Participants
Healthy Volunteers (Meningococcal Infection)
Primary: Groups 1a and 2a: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at Day 30 Post 12-Month…
Advanced Solid Tumors
Primary: Phase 1a (Arm A): Number of Participants Who Experienced at Least One Dose-limiting Toxicity (DLT) According to National Cancer Institute-Common Terminology Criteria for…
Moderate Chronic Plaque Psoriasis · Severe Chronic Plaque Psoriasis
Primary: Primary Endpoints: Pharmacokinetics (PK) - AUC — 2127.57; 2357.61 h*ug/mL
Cerebral Palsy · Prematurity · Early Intervention
Primary: Acceptability — 70 Participants
Juvenile Idiopathic Arthritis
Primary: Maximum Serum Concentration (Cmax) of Sarilumab at Week 12 — 7.57; 13.7; 22.0; 33.6 milligram per liter (mg/L)
Soft Tissue to Bone Fixation
Primary: Number of Participants With Clinical Success of the Study Devices in the Hip Over a Time Period of 6 Months After Intervention — 58; 0; 93; 0 Participants